Search the Newsreel

TRVI|Trevi Therapeutics Inc|Price:17.535|Chg%:+0.355

This article provides a detailed financial overview of Trevi Therapeutics Inc (TRVI), including its stock performance, market capitalization, and various financial statements. It highlights the company's latest earnings report, key financial indicators like EPS and net profit, and discusses assets, liabilities, and equity based …

Trevi Therapeutics (NASDAQ:TRVI) Downgraded by Wall Street Zen to "Sell"

Wall Street Zen downgraded Trevi Therapeutics (NASDAQ:TRVI) from "hold" to "sell", despite a generally positive consensus "Buy" rating and an average target price of $24.91 from other analysts. The company's stock last traded at $17.53, near its 12-month high, and recently missed earnings expectations. …

Siren L.L.C. Cuts Holdings in Trevi Therapeutics, Inc. $TRVI

Siren L.L.C. reduced its stake in Trevi Therapeutics (NASDAQ:TRVI) by 21.9% in the first quarter, selling 500,000 shares but still owning 1,786,867 shares valued at $21.3 million. Despite a wider-than-expected quarterly loss, analysts largely maintain a "Buy" rating for Trevi Therapeutics with an average …

Fifth Third Bancorp Invests $1.53 Million in Trevi Therapeutics, Inc. $TRVI

Fifth Third Bancorp has acquired a new stake of 128,325 shares, valued at $1.53 million, in Trevi Therapeutics during the first quarter. Other institutional investors have also significantly increased their holdings in the company, with 95.76% of Trevi Therapeutics stock now owned by institutional …

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

BMO Capital analyst Connor Mackay initiated coverage on Insmed Inc (NASDAQ: INSM) with an Outperform rating and a price target of $192. This article also highlights four other new analyst coverages: Axsome Therapeutics Inc (NASDAQ: AXSM) with an Outperform rating and $310 price target …

BMO Capital Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $36

BMO Capital has reiterated its Buy rating for Trevi Therapeutics (TRVI.US) and maintained its target price of $36. This indicates continued confidence from the analyst firm in the company's prospects.

Trevi Therapeutics (NASDAQ:TRVI) Rating Increased to Strong-Buy at BMO Capital Markets

BMO Capital Markets has upgraded Trevi Therapeutics (NASDAQ:TRVI) to a "strong-buy" rating. This upgrade contributes to a largely positive analyst outlook, with the consensus target price for TRVI shares sitting at $24.91, despite a recent earnings miss. The clinical-stage biopharma company, focused on non-opioid …

BMO Capital Initiates Trevi Therapeutics at Outperform With $36 Price Target

BMO Capital has initiated coverage on Trevi Therapeutics (TRVI) with an Outperform rating and set a price target of $36. This announcement follows B. Riley's recent adjustment of Trevi Therapeutics' price target to $31 from $21, maintaining a Buy rating. Trevi Therapeutics is a …

Trevi Therapeutics (NASDAQ:TRVI) Shares Down 5.1% - Here's Why

Trevi Therapeutics (NASDAQ:TRVI) saw its shares drop 5.1% on Monday, trading as low as $18.03 with below-average volume, following a previous close of $19.07. This decline occurred despite several analysts recently raising price targets and maintaining a "Moderate Buy" consensus rating with an average …

Trevi Therapeutics stock price target raised to $24 by H.C. Wainwright

H.C. Wainwright has increased its price target for Trevi Therapeutics (NASDAQ:TRVI) to $24 from $21, while maintaining a Buy rating. This adjustment follows GSK's decision not to advance camlipixant for refractory chronic cough, which H.C. Wainwright views as highly positive for Trevi Therapeutics. The …

HC Wainwright Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price

HC Wainwright has raised its price target for Trevi Therapeutics (NASDAQ:TRVI) to $24 from $21, maintaining a buy rating and suggesting a potential upside of 25.85%. Despite a recent quarterly EPS miss, other analysts also hold a generally positive outlook, contributing to a consensus …

_TRVI Surges As Trevi Therapeutics Draws Fresh Bullish Momentum

Trevi Therapeutics Inc. (TRVI) stock surged over 11% following optimistic investor response to clinical progress and a non-deal roadshow. Despite being a development-stage biotech with negative profitability and cash burn, the company boasts a strong balance sheet with substantial cash reserves and minimal debt. …

Trevi Therapeutics (TRVI) Is Up 6.9% After Haduvio Cough Data And New ILD Trial Plan - Has The Bull Case Changed?

Trevi Therapeutics Stock Jumps As Momentum Traders Pile In

Trevi Therapeutics Inc. (TRVI) stock has experienced an 11.6% jump, driven by positive drug trial news and aggressive buying interest from momentum traders. Despite being a clinical-stage biotech with negative profitability, the company maintains strong liquidity with $172M in cash and equivalents. The significant …

TRVI Jumps As Trevi Therapeutics Extends Rally On Heavy Interest

Trevi Therapeutics (TRVI) stock experienced an 11.6% surge following promising clinical data, generating significant investor and trading interest. The company is set to meet institutional investors in London, contributing to positive sentiment. Despite being a clinical-stage biotech with negative profitability, strong liquidity and low …

TRVI Jumps As Trevi Therapeutics Extends Bullish Run

Trevi Therapeutics Inc. (TRVI) stock has jumped by 11.6% due to optimism over its latest clinical trial developments and a Cantor Fitzgerald-hosted non-deal roadshow in London. Despite strong liquidity and no debt, the company is pre-revenue with negative returns and significant quarterly cash burn, …

TRVI Surges As Trevi Therapeutics Draws Aggressive Buyers

Trevi Therapeutics Inc. (TRVI) stock surged over 11% following strong clinical trial progress, boosting investor optimism. Despite being a clinical-stage, pre-revenue biotech with negative profitability, its strong balance sheet and upcoming non-deal roadshow are attracting institutional interest. Technical analysis suggests a short-term uptrend with …

Trevi Therapeutics Shares Surge 13% as Biopharma Investors Cheer Cough Drug Data at London Conference

Trevi Therapeutics (TRVI) Soars as Haduvio Taps Into $15B Addressable Market

Trevi Therapeutics grew its share prices by 9.85 percent on Friday to finish at $19.07 apiece, after management underscored strong clinical trial results from its treatment candidate for chronic cough. Speaking at a three-day conference in Europe, Trevi Therapeutics Inc (NASDAQ:TRVI) CEO Jennifer Good …

TRVI Stock Firms Up As Haduvio Story Hits Center Stage

Trevi Therapeutics Inc. (TRVI) stock is showing a strong upturn, driven by optimism surrounding its Haduvio clinical development and an aggressive outreach campaign. Management is engaging in a London non-deal roadshow hosted by Cantor Fitzgerald and participating in multiple industry events to boost visibility …

Trevi Therapeutics (NASDAQ:TRVI) Sees Strong Trading Volume - Should You Buy?

Trevi Therapeutics (NASDAQ:TRVI) experienced a significant surge in trading volume and stock price, with shares jumping to $20.12 on Friday. Analysts maintain a generally positive outlook, reiterating "buy" ratings and setting an average price target of $22.67, despite the company reporting a Q1 loss …

Stock Traders Buy Large Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI)

Trevi Therapeutics (NASDAQ:TRVI) experienced a significant surge in call option trading, with 13,996 call options bought on Wednesday, a 1,258% increase from the typical volume. This occurred despite a 0.43% share price drop to $17.48. Analysts maintain a "Buy" consensus rating with an average …